These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

451 related items for PubMed ID: 21108701

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies.
    Fabrizi F, Dixit V, Messa P, Martin P.
    J Viral Hepat; 2014 Oct; 21(10):681-9. PubMed ID: 25040244
    [Abstract] [Full Text] [Related]

  • 3. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M, Hernàndez J, Arenas MD, Carnicer F, Caramelo C, Fabrizi F.
    Kidney Blood Press Res; 2015 Oct; 40(3):258-65. PubMed ID: 25997572
    [Abstract] [Full Text] [Related]

  • 4. Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta-analysis of clinical trials.
    Fabrizi F, Dixit V, Messa P, Martin P.
    J Med Virol; 2010 May; 82(5):768-75. PubMed ID: 20336712
    [Abstract] [Full Text] [Related]

  • 5. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials.
    Fabrizi F, Dixit V, Messa P, Martin P.
    J Viral Hepat; 2008 Feb; 15(2):79-88. PubMed ID: 18184190
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.
    Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT.
    Int J Artif Organs; 2008 Apr; 31(4):295-302. PubMed ID: 18432584
    [Abstract] [Full Text] [Related]

  • 8. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
    Liu CH, Huang CF, Liu CJ, Dai CY, Liang CC, Huang JF, Hung PH, Tsai HB, Tsai MK, Chen SI, Lin JW, Yang SS, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Yu ML, Kao JH.
    Ann Intern Med; 2013 Dec 03; 159(11):729-38. PubMed ID: 24297189
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
    Ann Intern Med; 2013 Dec 03; 159(11):I-14. PubMed ID: 24297207
    [No Abstract] [Full Text] [Related]

  • 11. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P, Yang JM, Hou W, Song SD, Wang L, Lu W.
    Eur J Gastroenterol Hepatol; 2013 May 03; 25(5):601-5. PubMed ID: 23263720
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    Tseng PL, Chen TC, Chien YS, Hung CH, Yen YH, Chang KC, Tsai MC, Lin MT, Lee CT, Shen CH, Hu TH.
    Am J Kidney Dis; 2013 Oct 03; 62(4):789-95. PubMed ID: 23746377
    [Abstract] [Full Text] [Related]

  • 13. Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
    Marcellin P, Craxi A, Brandao-Mello CE, Di Bisceglie AM, Andreone P, Freilich B, Rajender Reddy K, Olveira Martín A, Teuber G, Messinger D, Hooper G, Wat C, Tatsch F, Jensen DM.
    J Clin Gastroenterol; 2013 Oct 03; 47(9):786-93. PubMed ID: 23442834
    [Abstract] [Full Text] [Related]

  • 14. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
    Pessôa MG, Cheinquer H, Almeida PR, Silva GF, Lima MP, Paraná R, Lacerda MA, Parise ER, Pernambuco JR, Pedrosa SS, Teixeira R, Sette H, Tatsch F.
    Ann Hepatol; 2012 Oct 03; 11(1):52-61. PubMed ID: 22166561
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe.
    Urbanek P, Oltman M, Ivanovski L, Rehák V, Messinger D, Tietz A, Husa P.
    Eur J Gastroenterol Hepatol; 2011 Nov 03; 23(11):1004-10. PubMed ID: 21904204
    [Abstract] [Full Text] [Related]

  • 16. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
    McHutchison J, Sulkowski M.
    J Viral Hepat; 2008 Jul 03; 15(7):475-81. PubMed ID: 18363672
    [Abstract] [Full Text] [Related]

  • 17. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients.
    Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P.
    Aliment Pharmacol Ther; 2003 Dec 03; 18(11-12):1071-81. PubMed ID: 14653826
    [Abstract] [Full Text] [Related]

  • 18. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy.
    Singal AG, Waljee AK, Shiffman M, Bacon BR, Schoenfeld PS.
    Aliment Pharmacol Ther; 2010 Oct 03; 32(8):969-83. PubMed ID: 20937042
    [Abstract] [Full Text] [Related]

  • 19. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.
    Zhao S, Liu E, Chen P, Cheng D, Lu S, Yu Q, Wang Y, Wei K, Yang P.
    Clin Ther; 2010 Aug 03; 32(9):1565-77. PubMed ID: 20974315
    [Abstract] [Full Text] [Related]

  • 20. Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies.
    Fabrizi F, Dixit V, Messa P.
    J Med Virol; 2013 Jun 03; 85(6):1019-27. PubMed ID: 23588727
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.